AstraZeneca and Daiichi Sankyo enter $6bn collaboration as pharma bets big on antibody-drug conjugates

DS-1062 is currently in development for the treatment of multiple tumours that commonly express the cell-surface glycoprotein TROP2. Credit: crystal light / Shutterstock.



  • AstraZeneca